Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma

Cancer Research

Volumn 66, Issue 16, 2006, Pages 8139-8146

  Chesler, Louis ^a   Schlieve, Chris ^a   Goldenberg, David D ^a   Kenney, Anna ^d   Kim, Grace ^b   McMillan, Alex ^c   Matthay, Katherine K ^a   Rowitch, David ^d   Weiss, William A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TYROSINE 3 MONOOXYGENASE; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME STABILITY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MOUSE; MYCN GENE; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TRANSGENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CHROMONES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE AMPLIFICATION; HUMANS; MORPHOLINES; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS;

EID: 33748068792     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2769     Document Type: Article

References (51)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Brodeur GM, Maris JM. Neuroblastoma. 4th ed. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: J.B. Lippincott Company, 2002. p. 895-938.
3. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9.
4. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-8.
5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage. Prog Clin Biol Res 1985;175: 105-13.
6. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313: 1111-6.
7. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-Myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
8. Schweigerer L, Breit S, Wenzel A, et al. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990;50: 4411-6.
9. Breit S, Ashman K, Wilting J, et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 2000;60:4596-601.
10. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-6.
11. Hatzi E, Breit S, Zoephel A, et al. MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. Adv Exp Med Biol 2000;476:239-48.
12. Goodman LA, Liu BC, Thiele CJ, et al. Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin Exp Metastasis 1997;15:130-9.
13. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16: 2985-95.
14. Weiss WA, Godfrey T, Francisco C, Bishop JM. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 2000;60:2483-7.
15. Hackett CS, Hodgson JG, Law ME, et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266-73.
16. Zimmerman KA, Yancopoulos GD, Collum RG, et al. Differential expression of myc family genes during murine development. Nature 1986;319:780-3.
17. Semsei I, Ma SY, Cutler RG. Tissue and age specific expression of the myc proto-oncogene family throughout the life span of the C57BL/6J mouse strain. Oncogene 1989;4:465-71.
18. Stanton BR, Parada LF. The N-myc proto-oncogene: developmental expression and in vivo site-directed mutagenesis. Brain Pathol 1992;2:71-83.
19. Lutz W, Stohr M, Schurmann J, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-12.
20. Cohn SL, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-13.
21. Martin DM, Feldman EL. Regulation of insulin-like growth factor-IL expression and its role in autocrine growth of human neuroblastoma cells. J Cell Physiol 1993;155:290-300.
22. Misawa A, Hosoi H, Arimoto A, et al. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 2000;60:64-9.
23. Slack A, Chen Z, Tonelli R, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 2005;102: 731-6.
24. Shohet JM, Hicks MJ, Pion SE, et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002;62:1123-8.
25. Holleran JL, Egorin MJ, Zuhowski EG, et al. Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal Biochem 2003;323:19-25.
26. Misawa A, Hosoi H, Tsuchiya K, Sugimoto T. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 2003;104:233-7.
27. Kim S, Kang J, Qiao J, et al. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg 2004;39:516-21.
28. Cohn SL, Salwen H, Quasney MW, et al. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene 1990;5:1821-7.
29. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003;130:15-28.
30. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 2004;131:217-28.
31. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of giycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9.
32. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436:807-11.
33. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
34. Matthay KK, Villablanca JG, Seeger RC, et al.; Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N England Journal of Medicine 1999;341: 1165-73.
35. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
36. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol 2000;18:1260-8.
37. Burkhart CA, Cheng AJ, Madafiglio J, et al. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 2003;95:1394-403.
38. Negroni A, Scarpa S, Romeo A, et al. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 1991;2:511-8.
39. Schmidt ML, Salwen HR, Manohar CF, Ikegaki N, Cohn SL. The biological effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ 1994;5:171-8.
40. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci 2003;24:366-76.
41. Yano H, Nakanishi S, Kimura K, et al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem 1993;268:25846-56.
42. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8.
43. Knight ZA, Chiang GG, Alaimo PJ, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 2004;12: 4749-59.
44. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
45. Zhou BP, Deng J, Xia W, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;6: 931-40.
46. Viatour P, Dejardin E, Warmer M, et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 2004;16:35-45.
47. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000;20:2423-35.
48. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003;278: 51606-12.
49. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-18.
50. Yaari S, Jacob-Hirsch J, Amariglio N, et al. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 2005;11:4321-30.
51. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 2004;3:1133-7.